Radin Daniel P, Lippa Arnold, Rana Sabhya, Fuller David D, Smith Jodi L, Cerne Rok, Witkin Jeffrey M
RespireRx Pharmaceuticals Inc., Glen Rock, NJ, USA.
RespireRx Pharmaceuticals Inc., Glen Rock, NJ, USA.
Pharmacol Biochem Behav. 2025 Mar;248:173967. doi: 10.1016/j.pbb.2025.173967. Epub 2025 Jan 31.
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptors (AMPA receptors or AMPARs) are involved in fast excitatory neurotransmission and as such control multiple important physiological processes. AMPARs also are involved in the dynamics of synaptic plasticity in the nervous system where they impact neuroplastic responses such as long-term facilitation and long-term potentiation that regulate biological functions ranging from breathing to cognition. AMPARs also regulate neurotrophic factors that are strategically involved in neural plastic changes in the nervous system. As with other major ionotropic receptors, modulation of AMPARs can have prominent effects on biological systems that can include marked tolerability issues. AMPAR potentiators (AMPAkines) are positive allosteric modulators of AMPARs which have therapeutic potential. Medicinal chemistry combined with new pharmacological findings have defined AMPAkines with favorable oral bioavailability and pharmacological safety parameters that enable clinical advancement of their therapeutic utility. AMPAkines are being investigated in patients with diverse neurological and psychiatric disorders including spinal cord injury (breathing and bladder function), cognition, attention-deficit-hyperactivity disorder, and major depressive disorder. The present discussion of this class of compounds focuses on their general value as therapeutics through their impact on synaptic plasticity.
α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体(AMPA受体)参与快速兴奋性神经传递,因此控制着多个重要的生理过程。AMPA受体还参与神经系统中突触可塑性的动态变化,在其中影响神经可塑性反应,如长期易化和长期增强,这些反应调节从呼吸到认知等多种生物学功能。AMPA受体还调节神经营养因子,这些因子在神经系统的神经可塑性变化中具有重要作用。与其他主要的离子型受体一样,AMPA受体的调节对生物系统可产生显著影响,这可能包括明显的耐受性问题。AMPA受体增强剂(AMPA激动剂)是具有治疗潜力的AMPA受体正性变构调节剂。药物化学与新的药理学研究结果相结合,已确定了具有良好口服生物利用度和药理安全性参数的AMPA激动剂,这使其治疗效用能够推进到临床阶段。目前正在对患有多种神经和精神疾病的患者进行AMPA激动剂的研究,这些疾病包括脊髓损伤(呼吸和膀胱功能)、认知障碍、注意力缺陷多动障碍和重度抑郁症。本文对这类化合物的讨论重点在于它们通过对突触可塑性的影响而具有的治疗价值。